Lilly waging battle to protect its coveted cancer drug: Drugmaker keeps rivals after Gemzar at bay through patent-infringement lawsuits
As Eli Lilly and Co. fends off allegations in an Alaskan courtroom involving its top-selling Zyprexa drug, the pharmaceutical giant is locked in another battle closer to home. The dispute winding through U.S. District Court in Indianapolis concerns the billion-dollar cancer drug Gemzar and Lilly’s attempts to prevent rivals from selling generic versions. While patent-infringement claims may be less intriguing than accusations that Lilly failed to warn doctors and patients about complications related to Zyprexa, the Gemzar case still has…